Clinical trials: CBD
COVID-19, Cardiovascular Diseases
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
- Conditions
- COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- NCT04615949
- Testing
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Where
- 20 sites in United States, Brazil and 1 more
- Volunteers
- 90 people
- Sponsor
- Cardiol Therapeutics Inc.
Epilepsy, Dravet Syndrome
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
- Trial name
- NCT02224703
- Testing
- GWP42003-P
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
Arthralgia, Breast Cancer
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
- Trial name
- NCT04754399
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Sclerosis
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
- Trial name
- NCT01610700
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Jazz Pharmaceuticals
Glioblastoma
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Glioblastoma (GBM) is the most common malignant brain tumor among adults. As the diagnosis is generally considered terminal, patients with GBM often suffer from anxiety and other comorbid conditions, including depression, pain…
- Trial name
- NCT05753007
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mclean Hospital
Urinary Stone
A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones
The purpose of this study is to determine if CBD oil has any effect on decreasing postoperative pain control following ureteroscopy for urinary stone disease, and to determine if CBD oil has any effect in decreasing the amount of…
- Trial name
- NCT04387617
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Parkinson Disease
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease.
- Trial name
- NCT05036473
- Testing
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Age-related Macular Degeneration
Carbidopa-levodopa in Neovascular AMD
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03022318
- Testing
- carbidopa-levodopa 25-100 mg tablets
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Drug Interaction
Cannabidiol and CES1 Interactions in Healthy Subjects
The proposed study will assess the drug interaction potential between oral cannabidiol (Epidiolex®) and the carboxylesterase 1 (CES1) substrate methylphenidate (Ritalin®) in 12 healthy research subjects
- Trial name
- NCT04603391
- Testing
- dl-Methylphenidate plus Cannabidiol
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Florida
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Alcohol Use Disorder, Post Traumatic Stress Disorder
Cannabidiol as a Treatment for AUD Comorbid With PTSD
This project aims to determine whether cannabidiol (CBD), a compound derived from the cannabis plant, is effective in treating alcohol use disorder (AUD) in individuals with comorbid posttraumatic stress disorder (PTSD).
- Trial name
- NCT03248167
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Anxiety
A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in adults. Participants will use a custom-formulated sublingual (under-the-tongue) solution of whole plant, hemp-derived CBD twice daily…
- Trial name
- NCT04286594
- Testing
- CBD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mclean Hospital
Age-related Macular Degeneration
Dose Ranging Study of Carbidopa-levodopa
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03023059
- Testing
- Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Parkinson's Disease
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
This is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2…
- Trial name
- ND0612/003 (NCT01883505)
- Testing
- ND0612, Entacapone
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- NeuroDerm Ltd.
Healthy Participants
A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol
The purpose of the study is to evaluate the pharmacodynamic (PD) interaction between steady-steady treatment with padsevonil (PSL) and Ethanol and the pharmacokinetic (PK) interaction between stead-state treatment with PSL and…
- Trial name
- NCT04039919
- Testing
- Padsevonil
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Atopic Dermatitis
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.
- Trial name
- NCT03824405
- Testing
- BTX 1204, Vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Botanix Pharmaceuticals
Pain
Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
The purpose of this double-blind, placebo-controlled study is to determine the analgesic effects of cannabidiol (CBD), a chemical constituent found in cannabis that does not have intoxicating effects.
- Trial name
- NCT02751359
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Attention Deficit Hyperactivity Disorder
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty…
- Trial name
- ADD201 (NCT00983814)
- Testing
- Droxidopa+Carbidopa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Chelsea Therapeutics
Epilepsy
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
This study consisted of 2 parts: a double-blind (DB) phase and an open-label extension (OLE) phase. Only the OLE phase is described in this record. The OLE phase was a safety study.
- Trial name
- NCT02564952
- Testing
- GWP42003-P, Clobazam
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Jazz Pharmaceuticals
Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy.
- Trial name
- NCT05388058
- Testing
- Cannabidiol, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic